Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Ali AmiryousefiLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-6317-3860
Jeremiah WalaDana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.ORCID 0000-0001-6591-1620
Jia-Ren LinLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-4702-7705
Brian William LabadieUniversity of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA.ORCID 0000-0002-3648-4663
Aishwarya AtmakuriUniversity of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA.ORCID 0000-0002-1648-3890
Zoltan MaligaLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-4209-7253
Eamon ToyeUniversity of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA.ORCID 0009-0003-6546-9387
Kiranj ChaudagarUniversity of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA.ORCID 0000-0002-8113-8516
Madeleine S TorcassoUniversity of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA.ORCID 0000-0003-0543-074X
Shannon CoyLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-0033-9031
Giuseppe Nicolo FanelliDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, 10021, USA.ORCID 0000-0001-7069-7980
Brigette KobsLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0009-0004-0467-0893
Fabio SocciarelliDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, 10021, USA.ORCID 0000-0001-9722-8164
Andreanne GagneUniversity Institute of Cardiology and Pulmonology of Quebec (CRIUCPQ), Laval University, 2725 Chemin Sainte-Foy, Quebec City, QC G1V 4G5, Canada.ORCID 0000-0002-3833-4159
Eliezer M Van AllenDana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.ORCID 0000-0002-0201-4444
Akash PatnaikUniversity of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA.ORCID 0000-0001-5306-0208
Peter SorgerLaboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-3364-1838
Funding
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6M
Molecular Determinants of Response and Resistance to EZH2 and PARP inhibition in Prostate CancerP50CA272390 · NCI · DANA-FARBER CANCER INST · PI Steven P. Balk, Himisha Beltran · 2023 to 2026
$12.0M
MOLECULAR IMMUNOLOGY AND TUMOR BIOLOGYT32CA009216 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Michael Langenau · 1985 to 2026
$10.6M
The Impact of DNA Damage Repair Abnormalities in Prostate CancerP01CA228696 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SOLIT, DAVID B. · 2019 to 2024
$8.7M
Visual Analytics for Exploration and Hypothesis Generation Using Highly MultiplexedSpatial Data of Tissues and TumorsU01CA284207 · NCI · HARVARD MEDICAL SCHOOL · PI PFISTER, HANSPETER, SANTAGATA, SANDRO · 2023 to 2025
$1.4M
High dimensional digital pathology to investigate the tumor micro environment and its impact on response to therapyR50CA252138 · NCI · HARVARD MEDICAL SCHOOL · PI MALIGA, ZOLTAN · 2020 to 2024
$1.0M
Dissecting the impact of tumor-immune spatial interactions in mismatch-repair stratified colorectal cancersK99CA300495 · NCI · DANA-FARBER CANCER INST · PI Jeremiah Wala · 2025 to 2026
The spatial organization and composition of the tumor-immune microenvironment (TME) play a critical role in shaping the progression of many solid cancers, but the organization of the TME in primary prostate cancer (PCa) remains poorly characterized. We therefore profiled the abundance and spatial distributions of major cell types involved in adaptive immunity in 29 radical prostatectomy specimens stratified into high (HGG; n=14) and low Gleason-grade (LGG; n=15). Compared to LGG, HGG PCa exhibited significantly greater B and T cell infiltration with many immune cells organized into clusters, some of which resembled tertiary lymphoid structures (TLSs). In HGG tumors, these clusters were dense, symmetric, rich in PD-1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Spatially organized lymphocytic microenvironments in high grade primary prostate tumors. · full record | OpenQuestion